Impact News +++ Carnival in charts: Passengers carried reaches 3.4M in FQ2; occupancy at 104% (SeekingAlpha) +++ CARNIVAL CORP Aktie +6,69%

KIORA PHARMACEUTICALS Aktie

>KIORA PHARMA Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>KIORA PHARMACEUTICALS Aktie

Name:

KIORA PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US49721T5074 / A40EG5

Symbol/ Ticker:

7EY (Frankfurt) / KPRX (NASDAQ)

Kürzel:

FRA:7EY, ETR:7EY, 7EY:GR, NASDAQ:KPRX

Index:

Webseite:

https://kiorapharma.com/

Marktkapitalisierung:

Umsatz:

EBITDA:

Gewinn je Aktie:

Schulden:

Liquide Mittel:

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

- / 0.4 / -

Gewinnm./ Eigenkapitalr.:

- / -41.13%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

KIORA PHARMACEUTICALS, KIORA PHARMA, KIORA PHARMACEUTICAL

Letzte Datenerhebung:

24.06.25

>KIORA PHARMA Eigentümer

Aktien: -

f.h. Aktien: -

Insider Eigner: 3.6%

Instit. Eigner: 45.65%

Leerverk. Aktien: 0.57%

>KIORA PHARMA Peer Group

ASPEN PHARMACARE ADR

CIDARA

CLENE

GENENTA

HEALTHCARE SERVICES GROUP

HOYA CORP ADR

LUNGLIFE AI

SOLVENTUM

STARPHARMA ADR

STRATA SKIN

>KIORA PHARMA Chart & Kurs - NASDAQ

>KIORA PHARMA News

03.06.25 - 13:06	Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia (Newsfile)
	Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option is exercised, Kiora will receive an additional mid-single dig......

09.05.25 - 13:33	Kiora Pharmaceuticals GAAP EPS of -$0.52 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.05.25 - 13:06	Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 (Newsfile)
	Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided an u......

05.05.25 - 13:12	Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy (Newsfile)
	Encinitas, California--(Newsfile Corp. - May 5, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the results from a preclinical study demonstrating KI......

04.04.25 - 13:06	Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference (Newsfile)
	Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthc......

25.03.25 - 12:21	Kiora Pharmaceuticals GAAP EPS of $0.87 beats by $0.01, revenue of $16.02M misses by $0.75M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.25 - 12:12	Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 (Newsfile)
	Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update o......

12.03.25 - 12:06	Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting (Newsfile)
	Encinitas, California--(Newsfile Corp. - March 12, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO-104 in a pr......

13.02.25 - 13:06	Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 (Newsfile)
	Encinitas, California--(Newsfile Corp. - February 13, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matte......

11.02.25 - 12:54	Kiora Pharmaceuticals, Inc.: Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema (Newsfile)
	Encinitas, California--(Newsfile Corp. - February 11, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLAR......

08.11.24 - 13:31	Kiora Pharmaceuticals GAAP EPS of -$0.81 misses by $0.05 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.11.24 - 13:07	Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies (Newsfile)
	Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided......

29.10.24 - 13:48	Kiora Pharmaceuticals gets approval to initiate mid-stage trial for eye disorder treatment (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.10.24 - 11:54	Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa (Newsfile)
	Encinitas, California--(Newsfile Corp. - October 29, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Pha......

11.06.24 - 08:27	XFRA : 7EY: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL KIORA PHARMACEUT. DL-,01 7EY US49721T5074 BAW/UFN...

11.06.24 - 08:15	XFRA : INSTRUMENT_SUSPENSION - US49721T5074 (XETRA)
	Instrument ID [19866492] (7EY - US49721T5074) suspended...

10.06.24 - 16:39	XFRA : ISIN Change (XETRA)
	Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen US49721T3095 Kiora Pharmaceuticals Inc. 10.06.2024 US49721T5074 Kiora Pharmaceuticals Inc. 11.06.2024 Tausch 9:1 US25058X1054 Desktop Metal Inc. 10.06.2024 US25058X3035 Desktop Metal Inc. 11.06.2024 Tausch 10:1...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Was man zu lang bedenkt, das wird bedenklich. - Sprichwort

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram